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Abstract
The increased risk of non-cardiovascular death in patients receiving clopidogrel or prasugrel in compar-
ison with the placebo group in the Dual Antiplatelet Therapy (DAPT) trial in contrast to the decreased 
risk of cardiovascular death and all-cause death seen in patients treated with low-dose ticagrelor in the 
EU label population of the PEGASUS-TIMI 54 trial, resulted in inclusion in the 2020 ESC NSTE-ACS  
guidelines the recommendation for use of clopidogrel or prasugrel only if the patient is not eligible for 
treatment with ticagrelor.
The prevalence of the primary outcome composed of cardiovascular death, stroke, or myocardial infarc-
tion was lower in the low-dose rivaroxaban and acetylsalicylic acid (ASA) group than in the ASA-alone 
group in the COMPASS trial. Moreover, all-cause mortality and cardiovascular mortality rates were 
lower in the rivaroxaban-plus-ASA group.
Comparison of the PEGASUS-TIMI 54 and COMPASS trial patient characteristics clearly shows that 
each of these treatment strategies should be addressed at different groups of patients. A greater benefit 
in post-acute coronary syndrome (ACS) patients with a high risk of ischemic events and without high 
bleeding risk may be expected with ASA and ticagrelor 60 mg b.i.d. when the therapy is continued with-
out interruption or with short interruption only after ACS. On the other hand, ASA and rivaroxaban 
2.5 mg b.i.d. seems to be a better option when indications for dual antithrombotic therapy (DATT) 
appear after a longer time from ACS (more than 2 years) and/or from cessation of DAPT (more than 
1 year) and in patients with multiple vascular bed atherosclerosis. Thus, both options of DATTs com-
plement each other rather than compete, as can be presumed from the recommendations. However,  
a direct comparison between these strategies should be tested in future clinical trials. (Cardiol J 2020; 
27, 6: 661–676)
Key words: prolonged antithrombotic therapy, chronic coronary syndrome, acute  
coronary syndrome, rivaroxaban, ticagrelor, clopidogrel, prasugrel
Introduction
Conventional antithrombotic therapy follow-
ing myocardial revascularization in acute coronary 
syndrome (ACS) patients comprises low-dose 
acetylsalicylic acid (ASA) and a P2Y12 receptor 
inhibitor — a combination referred to as dual an-
tiplatelet therapy (DAPT) — for up to 12 months 
after ACS [1–5]. However, increased risk of is-
chemic events persists in a substantial proportion 
of stable patients who have completed this period 
of DAPT after ACS [6–9].
According to the 2019 European Society of 
Cardiology (ESC) guidelines for the diagnosis 
and management of chronic coronary syndromes 
(CCS), “adding a second antithrombotic drug to 
ASA for long-term secondary prevention should be 
considered in patients with a high risk of ischemic 
events and without high bleeding risk” (class of 
recommendation IIa, level of evidence A) — as 
a dual antithrombotic therapy (DATT). This stra-
tegy “may be also considered in patients with 
at least a moderately increased risk of ischemic 
events and without high bleeding risk” (class of 
recommendation IIb, level of evidence A) [10].
The same document specifies risk factors 
defining high and moderate risk of ischemic com-
plications as well as high bleeding risk in patients 
with CCS, remaining in sinus rhythm (Table 1) [10]. 
The 2020 ESC guidelines for the management 
of ACSs in patients presenting without persistent 
ST-segment elevation modified the ischemic risk 
assessment (Table 2) and introduced a definition of 
a high risk of bleeding according to the Academic 
Research Consortium for High Bleeding Risk 
(Table 3) [11].
It is also expressed in the guidelines that 
prolonged antithrombotic therapy with a com-
bination of ASA and either a second antiplatelet 
agent or rivaroxaban at the “vascular dose” of 
2.5 mg b.i.d can be considered an option for patients 
with increased ischemic risk, who completed the 
standard 12-month DAPT following myocardial 
revascularization due to acute myocardial infarc-
tion (MI). The pivotal question that arises at this 
point is: which treatment should be applied to 
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which patient? Unfortunately, the indications and 
cautions mentioned in the guidelines are too vague 
and too limited to assist practicing physicians 
in making this choice in the real-world scenario 
(Table 4) [10, 11]. Thus, according to the authors of 
this position paper, the essential practical implica-
tions of these recommendations are still missing. 
Therefore, while designing the ELECTRA-SIRIO 
2 randomized clinical trial, aiming to assess strate-
gies of treatment in stable patients after MI, we 
decided to analyze ESC recommendations as well 
as available evidence regarding this issue [12, 13]. 
Trials supporting recommendation  
for DATT in CCS patients after MI
The ESC recommendations [10, 11] are based 
on several large randomized clinical trials con-
Table 1. Risk factors of high/moderate ischemic and high bleeding risk in patients with chronic  
coronary syndromes in sinus rhythm according to the 2019 ESC CCS guidelines [10].
High ischemic risk* High bleeding risk
Diffuse multivessel CAD with at least one  
of the following:
•	Diabetes mellitus requiring medication
•	Recurrent MI
•	PAD
•	CKD with eGFR 15–59 mL/min/1.73 m2 
 
•	Prior history of intracerebral hemorrhage or ischemic stroke
•	History of other intracranial pathology
•	Recent gastrointestinal bleeding or anemia due  
to possible gastrointestinal blood loss
•	Other gastrointestinal pathology associated with  
increased bleeding risk
•	Liver failure
•	Bleeding diathesis or coagulopathy
•	Extreme old age or frailty
•	Renal failure requiring dialysis or with eGFR < 15 mL/min/1.73 m2
*Moderate risk if any single factor, including HF, is present; CAD — coronary artery disease; CKD — chronic kidney disease;  
GFR — estimated glomerular filtration rate; HF — heart failure; MI — myocardial infarction; PAD — peripheral artery disease
Table 2. Risk factors of ischemic events — criteria for extended treatment with a second antithrombotic 
agent according to the 2020 ESC NSTE-ACS guidelines [11].
High thrombotic risk Moderate thrombotic risk
Complex CAD and at least 1 criterion Non-complex CAD and at least 1 criterion
Risk enhancers: •	DM requiring medication
•	Recurrent MI
•	Polyvascular disease (CAD plus PAD)




•	Polyvascular disease (CAD plus PAD)
•	Premature (< 45 years) or accelerated (new lesion  
within a 2-year time frame) CAD
•	Concomitant systemic inflammatory disease (e.g. human  
immunodeficiency virus, systemic lupus erythematosus,  
chronic arthritis)
•	CKD with eGFR 15–59 mL/min/1.73 m2 
Technical aspects:
•	≥ 3 stents implanted
•	≥ 3 lesions treated
•	Total stent length > 60 mm
•	Previous complex revascularization (left main, bifurcation  
stenting with ≥ 2 stents implanted, chronic total occlusion,  
stenting of last patent vessel)
•	Previous stent thrombosis on antiplatelet treatment
CAD — coronary artery disease; CKD — chronic kidney disease; DM — diabetes mellitus; eGFR — estimated glomerular filtration rate;  
MI — myocardial infarction; PAD — peripheral artery disease
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Table 3. Criteria for high bleeding risk according to the Academic Research Consortium for High Bleeding 
Risk at the time of percutaneous coronary intervention (bleeding risk is high if at least one major or 
two minor criteria are met) [11].
Major Minor
Anticipated use of long-term OAC
Severe or end-stage CKD (eGFR <30 mL/min)
Hemoglobin < 11 g/dL
Spontaneous bleeding requiring hospitalization  
and/ortransfusion in the past 6 months or at  
any time, if recurrent
Baseline thrombocytopenia 
(platelet count < 100 -109/L)
Chronic bleeding diathesis
Liver cirrhosis with portal hypertension
Active malignancy (excluding non-melanoma  
skin cancer) within the past 12 months
Previous spontaneous intracranial hemorrhage
Previous traumatic intracranial hemorrhage within  
the past 12 months
Presence of a brain arteriovenous malformation
Moderate or severe ischemic stroke within the  
past 6 months
Recent major surgery or major trauma within  
30 days prior to PCI
Non-deferrable major surgery on DAPT
Age ≥ 75 years
Moderate CKD (eGFR 30-59 mL/min)
Hemoglobin 11–12.9 g/dL for men or  
11–11.9 g/dL for women
Spontaneous bleeding requiring hospitalization  
and/or transfusion within the past 12 months,  
not meeting the major criterion
Chronic use of oral non-steroidal anti-inflammatory 
drugs or steroids
Ischemic stroke not meeting the major criterion
CKD — chronic kidney disease; DAPT — dual antiplatelet therapy; eGFR — estimated glomerular filtration rate; PCI — percutaneous coronary 
intervention; OAC — oral anticoagulant
Table 4. Treatment options for dual antithrombotic therapy in combination with acetylsalicylic acid 
(75–100 mg daily) in patients with a high or moderate risk of ischemic events and without high  
bleeding risk [10, 11].




Clopidogrel 75 mg o.d. Post-MI in patients  
who have tolerated DAPT  
for 1 year
DAPT
Prasugrel 10 mg o.d. or  
5 mg o.d.; if 
body weight  
< 60 kg or age  
> 75 years 
Post-PCI for MI in patients  
who have tolerated DAPT  
for 1 year
Age > 75 years DAPT 
TL-PAS
Ticagrelor 60 mg b.i.d. Post-MI in patients  
who have tolerated DAPT  
for 1 year 
PEGASUS-TIMI 54
Rivaroxaban 2.5 mg b.i.d. Post-MI > 1 year or  
multivessel CAD [10]
CrCl 15–29 mL/min COMPASS
or
Patients with CAD or  
symptomatic PAD at high  
risk of ischemic events [11]
CAD — coronary artery disease; CrCl — creatinine clearance; DAPT — dual antiplatelet therapy; MI — myocardial infarction; PAD — peripheral 
artery disease; PCI — percutaneous coronary intervention
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ducted in various populations (Table 5) [14–22]. 
Inclusion and exclusion criteria as well as the 
profile of patients enrolled in these trials should be 
used to determine indications for particular agents. 
Table 5. Clinical trials supporting the 2019 European Society of Cardiology (ESC) guidelines for the  
diagnosis and management of chronic coronary syndromes (according to citations) [14–22].
Study 
ClinicalTrials.gov  




Mauri et al.  
NEJM 2014 [14]
N = 9961 pts 
12 m after DES  
implantation 
 
clo 1 × 75 mg or  
pra 1 × 10 mg or  
1 × 5 mg in pts who 
weighed < 60 kg 
and ASA vs. placebo 
and ASA up to 30 m
DAPT beyond 1 year after 
DES placement reduced the 
risks of ST and MACCE, but 
was associated with an in-
creased risk of bleeding
Yeh et al. 
JACC 2015 [15]
N = 11,648 pts 
MI (n = 3576) 
No-MI (n = 8072) 
12 m after stent  
implantation 
DES (n = 9961) 
BMS (n = 1687)
clo 1 × 75 mg or  
pra 1 × 10 mg or  
1 × 5 mg in pts who 
weighed < 60 kg  
and ASA vs. placebo 
and ASA up to 30 m
30 m of DAPT after stent 
placement reduced risk of 
ST and MI in pts with and 





of the DAPT trial
Garratt et al.  
Circulation 2015  
[16]
N = 2191 pts 
12 m after TAXUS 
implantation
pra 1 × 10 mg or  
1 × 5 mg in pts who 
weighed < 60 kg  
and ASA vs. placebo 
and ASA up to 30 m
DAPT continued for 30 m af-
ter stent placement reduced 
ischemic events through 
reduction in MI and ST. With-
drawal of prasugrel was fol-
lowed by increase in MI after 
12 and 30 m therapy
PEGASUS-TIMI 54  
NCT01225562
Bonaca et al.  
NEJM 2015  
[17]
21,162 pts 
1 to 3 years after MI
tic 2 × 90 mg  
and ASA vs.  
tic 2 × 60 mg  
and ASA vs. placebo 
and ASA up to 36 m
DAPT reduced risk of CV 
death, MI, or stroke and in-
creased risk of major bleeding
Bhatt et al. 
JACC 2016  
[18]
21,162 pts 
DM (n = 6806) 
No-DM (n = 14,355) 
1 to 3 years after MI
In pts with DM DAPT reduced 
risk of recurrent ischemic 
events including CV death 
and CHD death
Bonaca et al.  
JACC 2016  
[19]
21,162 pts 
PAD (n = 1143) 
No-PAD (n = 20,017) 
1 to 3 years after MI
DAPT reduced MACE and 
MALE in PAD patients
Bonaca et al.  
EHJ 2016  
[20]
18,761 pts 
1 to 3 years after MI 
DAPT cessation prior 
to randomization:  
≤ 30 days (n = 7181) 
> 30 days to 1 year 
(n = 6501) 
> 1 year (n = 5079)
The benefit of DAPT was 
higher in pts continuing on or 
re-starting early after interrup-
tion of P2Y12 inhibition when 
compared with pts stable 
> 2 years from MI and off 
P2Y12 inhibitor > 1 year. The 
increase in bleeding events 
with ticagrelor was similar re-
gardless of this time interval




(n = 12,558 pts) 
No-MVD  
(n = 8600 pts) 
1 to 3 years after MI
In pts with MVD DAPT  
reduced risk of MACE  
and CE, and increased  
the risk of major bleeding,  
but not ICH or fatal bleeding
ASA — acetylsalicylic acid; BMS — bare-metal stent; CE — coronary events (coronary death, MI, or stent thrombosis); CHD — coronary heart 
disease; clo — clopidogrel; CV — cardiovascular; DAPT — dual antiplatelet therapy; DES — drug-eluting stent; DM — diabetes mellitus; 
ICH — intracranial hemorrhage; MACCE — major adverse CV and cerebrovascular events (death, MI, or stroke); MACE — major adverse CV 
events (CV death, MI, or stroke); MALE — major adverse limb events (acute limb ischemia or peripheral revascularization for ischemia); MI — 
myocardial infarction; MVD — multivessel disease; PAD — peripheral artery disease; pra — prasugrel; pts — patients; riv — rivaroxaban;  
ST — stent thrombosis; TAXUS — paclitaxel-eluting stent; tic — ticagrelor
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Dual antiplatelet therapy with ASA  
and a P2Y12 receptor inhibitor
Tolerability of DAPT during the recommended 
12-month therapy period and reduction of the 
risk of ischemic events outweighing the elevated 
bleeding risk is a premise for prolonged therapy 
with a P2Y12 receptor inhibitor and ASA [23–25]. 
According to the citations in the ESC guidelines 
[10, 11], indications to use clopidogrel, prasugrel, 
or ticagrelor in combination with ASA in patients 
with CCS after ACS are based on the data coming 
from the DAPT [14, 15, 26], TL-PAS [16], and 
PEGASUS-TIMI 54 trials [17–21].
The Dual Antiplatelet Therapy (DAPT) trial 
assessed the benefits and risks of 30 vs. 12 months 
of DAPT with a thienopyridine derivate (clopi-
dogrel or prasugrel) and ASA in patients with 
ischemic heart disease due to stenotic or occlusive 
lesions in either native coronary arteries or coro-
nary artery bypass grafting treated with stent im-
plantation [14, 15, 26]. The choice of thienopyridine 
and its dose followed the local standard of practice 
in the study sites. Out of the 11,648 randomized 
patients (9961 treated with drug-eluting stents 
[DES], 1687 with bare-metal stents [BMS]), 30.7% 
presented with MI. After 12 months of DAPT, 
patients were randomly assigned to continue treat-
ment with thienopyridine or placebo for another 
18 months; all patients continued receiving ASA. 
Continuation of DAPT beyond 1 year after DES 
implantation, as compared with ASA therapy alone, 
significantly reduced the risk of stent thrombosis 
(0.4% vs. 1.4%; hazard ratio [HR] 0.29; p < 0.001), 
MI (2.1% vs. 4.1%; HR 0.47; p < 0.001), MI not 
related to stent thrombosis (1.8% vs. 2.9%; HR 
0.59; p < 0.001), and major adverse cardiovascu-
lar and cerebrovascular events (4.3% vs. 5.9%; 
HR 0.71 (95% confidence interval [CI] 0.59–0.85; 
p < 0.001), but was associated with an increased 
risk of moderate or severe bleeding (2.5% vs. 1.6%, 
p = 0.001). An elevated risk of stent thrombosis 
and MI was observed in both groups during the first 
3 months after discontinuation of thienopyridine 
treatment [14]. The risk of death from any cause 
was higher in the group that continued to receive 
thienopyridine as compared with the placebo group 
(2.0% vs. 1.5%; HR 1.36; p = 0.05). During the 
secondary-analysis period (month 12 to month 33) 
the rate of all-cause mortality was higher in the 
thienopyridine group: 2.3% vs. 1.8%, respectively 
(HR 1.36; p = 0.04). The difference was driven by 
an increase in the number of non-cardiovascular 
deaths (mainly related to bleeding, fatal trauma, 
and cancer) in the thienopyridine group. It is not 
clear what proportion of these deaths was related 
to evaluated treatment, as some of the deaths 
not defined as bleeding-related were mediated by 
bleeding [14]. 
The TAXUS Liberté Post Approval Study 
(TL-PAS) — a subpopulation of DAPT — included 
patients who were treated with a TAXUS Liberté 
paclitaxel-eluting stent and prasugrel [16]. The 
TL-PAS patients represented the largest group 
of patients implanted with a paclitaxel-eluting 
coronary stent, and the largest cohort receiving 
prasugrel, enrolled into the DAPT study. The oc-
currence of the DAPT study co-primary composite 
end point (death, MI, or stroke) was lower in pa-
tients receiving the combination of prasugrel and 
ASA for 30 months compared with 12 months (3.7% 
vs. 8.8%; HR 0.407; p < 0.001) solely through the 
Table 5 (cont.). Clinical trials supporting the 2019 European Society of Cardiology (ESC) guidelines for 
the diagnosis and management of chronic coronary syndromes (according to citations) [14–22].
Study 
ClinicalTrials.gov  
Publication Patients Study treatment Outcome
COMPASS 
NCT01776424
Eikelboom et al. 
NEJM 2017  
[22]
27,395 pts 
with stable  
atherosclerotic  
vascular disease
riv 2 × 2.5 mg and 
ASA vs. riv 2 × 5 mg 
and placebo vs.  
placebo and ASA
Pts assigned to riv plus ASA 
had better CV outcomes and 
more major bleeding events 
than those assigned to ASA 
alone. Riv alone did not result 
in better CV outcomes than 
ASA alone and resulted in 
more major bleeding events
ASA — acetylsalicylic acid; BMS — bare-metal stent; CE — coronary events (coronary death, MI, or stent thrombosis); CHD — coronary heart 
disease; clo — clopidogrel; CV — cardiovascular; DAPT — dual antiplatelet therapy; DES — drug-eluting stent; DM — diabetes mellitus; 
ICH — intracranial hemorrhage; MACCE — major adverse CV and cerebrovascular events (death, MI, or stroke); MACE — major adverse CV 
events (CV death, MI, or stroke); MALE — major adverse limb events (acute limb ischemia or peripheral revascularization for ischemia); MI — 
myocardial infarction; MVD — multivessel disease; PAD — peripheral artery disease; pra — prasugrel; pts — patients; riv — rivaroxaban;  
ST — stent thrombosis; TAXUS — paclitaxel-eluting stent; tic — ticagrelor
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reduction in MI rate (1.9% vs. 7.1%; HR 0.255; 
p < 0.001). The incidence of stent thrombosis was 
also lower with longer dual antiplatelet therapy 
(0.2% vs. 2.9%; HR 0.063; p < 0.001). Rates of 
death and stroke were similar in both groups. With-
drawal of prasugrel was followed by an increase 
in the rate of MI after both 12 and 30 months 
of therapy. The optimal duration of DAPT with 
prasugrel after implantation of a TAXUS Liberté 
paclitaxel-eluting stent remains unknown, but it 
appears to be longer than 30 months [16]. 
The results of this study are of limited rel-
evance because paclitaxel-eluting stents are no 
longer used due to the increased risk of major ad-
verse cardiac events mainly driven by a higher rate 
of MI, target-vessel revascularization, and stent 
thrombosis, especially a very late one [27, 28].
The PEGASUS-TIMI 54 (Prevention of Car-
diovascular Events in Patients with Prior Heart 
Attack Using Ticagrelor Compared to Placebo on 
a Background of Aspirin-Thrombolysis In Myocar-
dial Infarction 54) trial was designed to test the 
hypothesis that long-term therapy with ticagrelor 
added to low-dose ASA reduces the risk of major 
adverse cardiovascular events (MACE) in stable 
patients with a history of MI [17]. Patients were 
randomized in a 1:1:1 ratio to receive ticagrelor 
90 mg b.i.d., 60 mg b.i.d., or placebo. Reduction 
in the primary end point (MACE: composite of 
cardiovascular death, MI, or stroke) in both ticagre-
lor-treated study arms (7.85% and 7.77%, respec-
tively) vs. placebo (9.04%) at 3 years of follow-up 
was observed (HR for ticagrelor 90 mg b.i.d. vs. 
placebo, 0.85; p = 0.008; HR for ticagrelor 60 mg 
b.i.d. vs. placebo, 0.84; p = 0.004). Differences 
promoting therapy with a combination of ticagrelor 
and ASA over ASA alone were shown in the rate 
of MI (HR for ticagrelor 90 mg b.i.d. vs. placebo, 
0.81; p = 0.01; HR for ticagrelor 60 mg b.i.d. vs. 
placebo, 0.84; p = 0.03) and in the rate of stroke; 
however, in the latter case, only for ticagrelor 
60 mg b.i.d. vs. placebo (1.47% vs. 1.94%; HR 
0.75; p = 0.03). As far as safety of the treatment 
is concerned, major bleedings were more frequent 
in individuals receiving ticagrelor, either 90 mg 
b.i.d. or 60 mg b.i.d., compared with those in 
whom placebo was administered, 2.6% and 2.3% 
vs. 1.06%, respectively (HR for ticagrelor 90 mg 
b.i.d., 2.69; p < 0.001; HR for ticagrelor 60 mg, 
2.32; p < 0.001); however, no differences were 
found in the rates of fatal or non-fatal intracranial 
bleeding episodes in the ticagrelor-treated arms 
as compared with placebo (0.63% and 0.71%, vs. 
0.60%, respectively) [17]. 
Out of the 21,162 patients enrolled in the 
PEGASUS-TIMI 54 trial, 6806 had diabetes [18]. 
Because patients with diabetes have a higher risk 
of MACE, the absolute risk reduction tended to be 
greater in patients with vs. without diabetes (1.5% 
vs. 1.1%, respectively). Moreover, in patients with 
diabetes, ticagrelor reduced the rate of cardiovas-
cular mortality by 22% (p < 0.05) and coronary 
heart disease deaths by 34% (p = 0.01) [18]. 
In a subset of patients with peripheral artery 
disease (PAD), the greater absolute risk reduction 
in MACE (4.1%) was due to their higher abso-
lute ischemic risk [19]. The 60 mg b.i.d. dose of 
ticagrelor showed a particularly favorable impact 
on cardiovascular as well as all-cause mortality 
in comparison with placebo (4.2% vs. 9.6%; HR 
0.47; p = 0.014 and 8.2% vs. 14.0%; HR 0.52; 
p = 0.0074) [19]. In patients with multi-vessel dis-
ease, ticagrelor reduced the risk of MACE (7.94% 
vs. 9.37%; HR 0.82; p = 0.004), including reduction 
in coronary death (HR 0.64; p = 0.002) [21]. 
The analysis of results according to the time 
between randomization to the PEGASUS-TIMI 54 
trial and previous cessation of DAPT with P2Y12 
inhibitor and ASA after MI revealed better out-
comes in patients who had stopped DAPT more 
recently [20]. Patients were categorized by time 
from the last P2Y12 receptor inhibitor dose (days: 
≤ 30, 30–360, > 360). The benefit of ticagrelor (re-
duction in MACE rate) depended on the time from 
the last dose, and was more pronounced in patients 
continuing on or re-starting after only a brief inter-
ruption of P2Y12 inhibition than in patients who 
had proven themselves stable more than 2 years 
from MI and off P2Y12 inhibitor therapy for more 
than a year with hazard ratios for ticagrelor (pooled 
doses) vs. placebo of 0.73; p < 0.001, 0.86; p = 0.11, 
and 1.01; p = 0.96, respectively, by category 
(P-trend for interaction < 0.001). The benefit within 
30 days of stopping DAPT was similar regardless 
of time from MI. On the other hand, the increase in 
bleeding events with ticagrelor was similar regard-
less of this time interval [20]. According to these 
results, the European Medicines Agency approved 
European (EU) label recommends that treatment 
with ticagrelor 60 mg b.i.d. may be a continuation 
of the initial one-year treatment with ticagrelor 
90 mg b.i.d. (or other P2Y12 receptor inhibitor) in 
high-risk patients with MI [29]. Treatment with 
ticagrelor 60 mg b.i.d. can also be initiated up to 
2 years from the MI, or within 1 year after stop-
ping previous P2Y12 receptor inhibitor treatment. 
Therefore, an analysis evaluating the efficacy 
and safety of treatment in a PEGASUS-TIMI 54 
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subpopulation receiving low-dose ticagrelor recom-
mended for treatment in the EU label (n = 10,779: 
5388 in the ticagrelor 60 mg b.i.d. and 5391 in the 
placebo group) was performed [30]. DATT with 
ticagrelor 60 mg b.i.d. in the EU label population 
reduced the composite of cardiovascular death, 
MI, or stroke (7.9% vs. 9.6%; HR 0.80; p = 0.001). 
Moreover, in the EU label population this DATT 
strategy was associated with lower hazard ratios for 
cardiovascular death (0.71; p = 0.0041), MI (0.83; 
p = 0.041), and all-cause death (0.80; p = 0.018). 
Better efficacy was associated with a higher risk of 
Thrombolysis in Myocardial Infarction (TIMI) ma-
jor bleeding occurrence (2.5% vs. 1.1%; HR 2.36; 
p < 0.001), without an increase in fatal or intracranial 
bleedings, confirming a favorable benefit-risk bal-
ance for long-term ticagrelor 60 mg b.i.d. in this 
population [30, 31].
Ticagrelor proved to be similarly effective in 
patients with and without a history of coronary 
stenting, suggesting also a benefit in the preven-
tion of spontaneous atherothrombotic events not 
related to stent thrombosis [32].
The increased risk of non-cardiovascular 
death in patients receiving clopidogrel or prasu-
grel in comparison with the placebo group in the 
DAPT trial [14], in contrast to the decreased risk 
of cardiovascular death and all-cause death seen 
in patients treated with low-dose ticagrelor in the 
EU label population of the PEGASUS-TIMI 54 
trial [30], resulted in inclusion in the 2020 ESC 
NSTE-ACS guidelines the recommendation for 
use of clopidogrel or prasugrel only if the patient 
is not eligible for treatment with ticagrelor [11].
Dual antithrombotic therapy  
with ASA and rivaroxaban
Continued occurrence of recurrent ischemic 
events despite treatment with potent P2Y12 re-
ceptor inhibitors (prasugrel and ticagrelor) and 
ASA stimulated interest in exploring the efficacy 
and safety of direct oral anticoagulants in patients 
with ACS [33].
Reduction in ischemic event risk with rivar-
oxaban (2.5 mg or 5 mg b.i.d.) added to standard 
DAPT with ASA and a P2Y12 inhibitor has been 
shown to be superior to placebo in patients with 
ACS in the ATLAS ACS 2-TIMI 51 trial. However, 
only the 2.5 mg b.i.d. dose of rivaroxaban was as-
sociated with a survival benefit. Moreover, the 
increase in risk of major bleeding was lower with 
the 2.5 mg b.i.d. rivaroxaban dose [34]. These 
results provided a promising basis for low-dose ri-
varoxaban in addition to ASA in patients with CCS.
According to the citations in the ESC guide-
lines [10, 11], the indications for use of rivaroxaban 
in combination with ASA in patients with CCS after 
ACS are based on the results of the Cardiovascular 
Outcomes for People Using Anticoagulation Strate-
gies (COMPASS) trial [22, 35–37]. 
The COMPASS trial was aimed to test the hy-
pothesis that rivaroxaban in combination with ASA 
or given alone is more effective than ASA alone 
in preventing recurrent cardiovascular events, 
with acceptable safety, in patients with stable 
atherosclerotic vascular disease [22]. Patients 
with stable atherosclerotic vascular disease were 
randomly assigned to receive rivaroxaban (2.5 mg 
b.i.d.) plus ASA (100 mg q.d.), rivaroxaban (5 mg 
b.i.d.), or ASA (100 mg q.d.) in a 1:1:1 ratio. The 
prevalence of the primary outcome composed of 
cardiovascular death, stroke, or MI was lower in 
the rivaroxaban-plus-ASA group than in the ASA-
-alone group (4.1% vs. 5.4%; HR 0.76; p < 0.001). 
Moreover, all-cause mortality and cardiovascular 
mortality rates were lower in the rivaroxaban-plus-
-ASA group as compared with the ASA-alone group 
(for all-cause mortality: 3.4% vs. 4.1%; HR 0.82; 
p = 0.01; for cardiovascular mortality: 1.7% vs. 
2.2%; HR 0.78; p = 0.02). Superiority of DATT with 
low rivaroxaban dose and ASA over ASA alone was 
observed also for the risk of stroke (0.9% vs. 1.6%; 
HR 0.58; p < 0.001). This benefit was achieved 
at the cost of a higher major bleeding rate in the 
rivaroxaban-plus-ASA group (3.1% vs. 1.9%; HR 
1.70; p < 0.001), but with no significant difference 
in fatal bleeding (0.2% vs. 0.1%; HR 1.49; p = 0.32). 
A substantial reduction in ischemic strokes and 
embolic/uncertain strokes with low-dose rivaroxa-
ban and ASA was also confirmed in an additional 
analysis of this trial [38], suggesting a potential 
for this new antithrombotic option in primary and 
secondary stroke prevention. Favorable clinical 
outcome with DATT was also confirmed by an 
analysis of net clinical benefit [37].
No clinical benefit with regard to the primary 
outcome was observed in the 5 mg b.i.d. rivaroxa-
ban-alone group as compared with the ASA-alone 
group, but major bleeding events occurred more fre-
quently in the rivaroxaban-alone group. The study 
was prematurely terminated due to the superiority 
of the rivaroxaban-plus-ASA therapy after a mean 
follow-up of 23 months [22]. In patients with stable 
coronary artery disease (CAD) (n = 24,824), ad-
dition of rivaroxaban to ASA resulted in a similar 
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impact on the efficacy and safety of the treatment. 
DATT with rivaroxaban and ASA compared with 
ASA alone reduced the primary outcome (4% vs. 
6%; HR 0.74; p < 0.0001) and mortality (3% vs. 
4%; HR 0.77; p = 0.0012), but increased the rate of 
major bleeding (3% vs. 2%; HR 1.66; p < 0.0001) 
[35]. There were 17,028 patients (69%) with a his-
tory of previous MI; however, patients who gained 
the most in the PEGASUS-TIMI 54 trial (EU label 
population), i.e. those between the first and sec-
ond year after MI (72.9% of the total population), 
in the COMPASS trial accounted for only 9.3% 
of all patients with CAD. Together with patients 
within the first year after MI, this subpopulation 
of CAD patients in the COMPASS trial accounted 
for 14.3%, and according to a subgroup analysis the 
clinical benefit in terms of the primary outcome 
was not significant, in contrast to patients over 
5 years after MI [35]. 
Of the 16,560 patients with CCS in the COM-
PASS trial, 9862 (59.6%) patients had a history 
of previous percutaneous coronary intervention 
(PCI). The average time from PCI to randomization 
was 5.4 years. DATT with rivaroxaban compared 
with ASA alone in patients with or without previous 
PCI resulted in consistent MACE reduction (PCI: 
4.0% vs. 5.5%; HR 0.74; no PCI: 4.4% vs. 5.7%; 
HR 0.76; P-interaction = 0.85) and mortality reduc-
tion (PCI: 2.5% vs. 3.5%; HR 0.73; no PCI: 4.1% 
vs. 5.0%; HR 0.80; P-interaction = 0.59), but was 
associated with an increased rate of major bleeding 
(PCI: 3.3% vs. 2.0%; HR 1.72; no PCI: 2.9% vs. 
1.8%; HR 1.58, P-interaction = 0.68) [38]. Among 
those with previous PCI 1 year and beyond, the 
effects on MACE and mortality were consistent ir-
respective of time since last PCI and irrespective of 
a history of previous MI (P-interaction = 0.64) [39].
The combination of ASA plus rivaroxaban 
provided a similar relative degree of clinical ben-
efit in patients with and without diabetes mellitus. 
However, due to a higher baseline risk, the absolute 
benefits appeared larger in patients with diabetes 
mellitus, including a 3-fold greater reduction in 
all-cause mortality [36].
Patient characteristics in trials  
supporting recommendation for  
DATT in CCS patients after MI
Different inclusion and exclusion criteria in 
trials supporting the ESC guidelines [10] displayed 
in Table 6 lead to several pivotal differences in the 
characteristics of patients enrolled to these tri-
als (Table 7). Patients after ischemic stroke were 
included into the DAPT, TL-PAS, and COMPASS 
trials, but not into the PEGASUS-TIMI 54 trial. Only 
36% of subjects in the COMPASS trial had a history 
of previous PCI, while in the PEGASUS-TIMI 54, 
DAPT, and TL-PAS trials this percentage was 83%, 
100%, and 100%, respectively. All patients in the 
PEGASUS-TIMI 54, 62.6% in COMPASS, and only 
21.6% in the DAPT trial had a history of MI before 
enrolment into the trial. Finally, a huge difference re-
garding the interval between MI and randomization 
in the PEGASUS-TIMI 54 (1.7 year) and COMPASS 
trial (7.1 years) should be highlighted. Several minor 
differences between the investigated populations 
should also be noted [17–22, 34–36] (Table 7).
In the DAPT trial, an increased all-cause mor-
tality risk was observed in patients on prolonged 
treatment with clopidogrel or prasugrel and ASA. 
Moreover, the reported clinical benefit of this 
therapeutic strategy (DAPT trial and TL-PAS) was 
mainly dependent on reduction of the risk of MI and 
stent thrombosis in patients in whom a paclitaxel-
-eluting coronary stent was implanted, while this 
type of stent is no longer in use due to increased 
risk of MI, target-vessel revascularization, and stent 
thrombosis, especially very late one. Furthermore, 
the results of separate analyses for clopidogrel 
and prasugrel failed to demonstrate any significant 
impact on the clinical outcome [14–16, 26–28]. 
When considering treatment with clopidogrel, its 
volatile pharmacodynamic effects related to variable 
efficiency of conversion to its active metabolite, 
partly associated with loss-of-function variants in 
the CYP2C19 gene, leading to a lack of efficacy in 
some patients, should be taken into account [40–43].
Thus, the rationale to recommend prolonged 
DAPT with any of these drugs, in our opinion, is 
limited.
In contrast to the DAPT trial and TL-PAS, the 
messages provided by the PEGASUS-TIMI 54 and 
COMPASS trials seem to be clear and unambigu-
ously positive for DATT with ticagrelor 60 mg mg 
b.i.d. and rivaroxaban 2.5 mg b.i.d., respectively. 
However, the indications for DATT including tica-
grelor or rivaroxaban need to be clarified because the 
overlapping of eligibility between PEGASUS-TIMI 
54 and COMPASS criteria (Fig. 1) is not reflected 
by overlapping of evaluated populations according 
to patient characteristics of both trials (Table 6, 7).
PEGASUS-TIMI 54 versus  
COMPASS approach
In an attempt to answer the question: “Who 
could benefit most from the PEGASUS-TIMI 54 
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> 18 years of age
PCI with stent
12 months free from MI, 
stroke, repeat coronary 
revascularization, ST, 
and moderate or severe 
bleeding, and compliant
> 50 years of age
MI occurring 1 to 3 years 
prior to randomization  
and at least 1 of the  
following risk factors:
 — age ≥ 65 years of age
 — diabetes mellitus 
 — second prior MI  
(> 1 year ago)
 — multivessel CAD 
 — chronic renal dysfunc-
tion CrCl < 60 mL/min
 — on treatment and toler-
ating ASA 75–150 mg 
once daily 
CAD defined as 1 of the following: 
 — MI within the last 20 years
 — multivessel CAD with symptoms or 
with history of stable or unstable 
angina
 — multivessel PCI or CABG surgery
Subjects with CAD must also meet at 
least 1 of the following criteria:
 — age ≥ 65, or
 — age < 65
Documented atherosclerosis or revas-
cularization involving at least 2 vascular 
beds or at least 2 additional risk factors:
 — current smoker 
 — diabetes mellitus
 — renal dysfunction with eGFR  
< 60 mL/min
 — heart failure
 — ischemic stroke ≥ 1 month ago
PAD defined as one of the following:  
 — previous revascularization for PAD
 — previous limb or foot amputation for 
arterial vascular disease 
 — history of intermittent claudication 
and at least 1 of the following
Previous carotid revascularization or 
asymptomatic carotid artery stenosis  









sitating discontinuation  
of antiplatelet therapy
Life expectancy < 3 years
Concurrent enrolment in 
another study
Subjects on oral antico-
agulants
Hypersensitivity or aller-
gies to one of the drugs
Subjects unable to give 
informed consent
Subject treated with both 
DES and BMS during the 
index procedure
Switched thienopyridine 
type or dose within  
6 months before  
randomization
PCI or cardiac surgery  
between 6 weeks post  
index procedure and  
randomization
Planned use of ADP recep-
tor blockers, dipyridamole, 
or cilostazol
Planned coronary, cerebro-
vascular, or peripheral arte-
rial revascularization
Need for chronic antico-
agulation
Known bleeding diathesis 
or coagulation disorder
Patients with:
 — a history of intracranial 
bleeding 
 — central nervous system 
tumor or intracranial 
vascular abnormality
 — intracranial or spinal 
cord surgery within  
5 years
 — gastrointestinal bleed-
ing within the past  
6 months, or major  
surgery within 30 days
History of ischemic stroke
Patients considered to 
be at risk of bradycardic 
events
CABG in the past 5 years
Known severe liver disease
Renal failure requiring  
dialysis or anticipated  
need for dialysis during  
the course of the study
Pregnancy or lactation
Life expectancy < 1 year
High risk of bleeding
Need for dual antiplatelet therapy, other 
non-ASA antiplatelet therapy, or oral 
anticoagulant therapy
Stroke within 1 month or any history of 
hemorrhagic or lacunar stroke
Severe heart failure with known ejection 
fraction < 30% or New York Heart  
Association class III or IV symptoms
eGFR < 15 mL/min
Any known hepatic disease associated 
with coagulopathy
Known non-cardiovascular disease that 
is associated with poor prognosis (e.g. 
metastatic cancer) or that increases  
the risk of an adverse reaction to study 
interventions
History of hypersensitivity or known 
contraindication for rivaroxaban, ASA, 
pantoprazole, or excipients
ASA — acetylsalicylic acid; BMS — bare-metal stent; CABG — coronary artery bypass grafting; CAD — coronary artery disease; CrCl —  
creatinine clearance; DES — drug-eluting stent; eGFR — estimated glomerular filtration rate; MI — myocardial infarction; PAD — peripheral 
artery disease; PCI — percutaneous coronary intervention; ST — stent thrombosis
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Figure 1. Overlapping of PEGASUS-TIMI 54 and COMPASS trials inclusion criteria; DAPT — dual antiplatelet therapy; 
CAD — coronary artery disease; CABG — coronary artery bypass grafting; EF — ejection fraction; NYHA — New York 
Heart Association; PCI — percutaneous coronary intervention.
ASA
+ Ticagrelor 60 mg b.i.d.
ASA
+ Rivaroxaban 2.5 mg b.i.d.
• No history of ischemic stroke
• No risk of bradycardia
• No recent CABG
• CAD
• High ischemic risk outweighing
 bleeding risk
• Good tolerance of DAPT
•  > 12 months post PCI
• Diabetes mellitus
• Non end-stage chronic kidney 
 disease
• No indication for P2Y12
• No chronic heart failure
 (NYHA III/IV class or 
 EF < 30%)
• Previous ischemic stroke
 (except last month)












Number of patients 11,648 21,162 27,395
Number of CAD patients 11,648 21,162 24,824
CAD patients [%] 100 100 90.6
Age [years] 61.7 ± 10.2 65.3 ± 8.4 68.2 ± 7.9
Female sex [%] 25.4 23.9 22.0
Diabetes mellitus [%] 30.6 32.2 37.8
Hypertension [%] 74.9 77.5 75.3
Tobacco use [%] 24.6 16.7 21.4
Previous stroke [%] 3.3 0 3.8
Heart failure [%] 4.7 20.0 21.5
Peripheral arterial disease [%] 5.8 5.4 27.3
Chronic kidney disease (GFR < 60 mL/min) [%] 4.23 23,2 23.1
Previous PCI [%] 100 83.0 36
Previous MI [%] 21.6 100 62.2
Previous STEMI [%] 10.5 53.6 NA
Years since MI [median] 1 1.7 7.1
Patients with previous MI within 1–2 years [%] NA 72.9* 9.3**
*based on DAPT cessation 
**out of CAD subpopulation
Duration of study treatment [months] 30 33 23
Discontinuation rate in the study arm [%] 21.4 28.7* 16.5**
*ticagrelor 60 mg b.i.d. 
**rivaroxaban 2.5 mg b.i.d. + ASA
ASA — acetylsalicylic acid; CAD — coronary artery disease; DAPT — dual antiplatelet therapy; GFR — glomerular filtration rate; MI — myo-
cardial infarction; NA — non available; PCI — percutaneous coronary intervention; STEMI — ST-segment elevation myocardial infarction
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rather than from the COMPASS approach among 
CAD patients?”, Brunetti et al. [44] proposed 
a flow-chart for identification of the optimal treat-
ment, based solely on the PEGASUS-TIMI 54 and 
COMPASS trial inclusion and exclusion criteria. 
According to the authors, the choice between 
rivaroxaban and ticagrelor should be based on the 
presence of severe renal failure (defined as esti-
mated glomerular filtration rate < 15 mL/min), 
severe heart failure (ejection fraction < 30% or 
New York Heart Association [NYHA] class III or IV 
symptoms), or strong interaction with CYP3A4 or 
P-glycoprotein, the presence of which indicates the 
PEGASUS-TIMI 54 approach [44]. The proposed 
strategy may be helpful in some, but probably few 
subjects, leaving the dilemma of choosing between 
ticagrelor and rivaroxaban unresolved in a majority 
of post-MI patients with a high risk of ischemic 
events and without high bleeding risk. 
A similar algorithm was developed by Capo-
danno et al. [45]; however, in this case previous 
ischemic stroke was the only differentiating factor 
between the recommended DATT strategies. There 
is no doubt that this factor should be taken into ac-
count due to the differences in the PEGASUS-TIMI 
54 and COMPASS inclusion and exclusion criteria. 
Nevertheless, considering that none of the patients 
included in the PEGASUS-TIMI 54 trial and only 
3.8% of patients in the COMPASS trial experienced 
ischemic stroke previously (Table 7), the evidence 
to support this recommendation is weak, and the 
vast majority of post-MI subjects requiring DATT 
will remain without clear indications, with both 
strategies deemed by the authors equally accept-
able in patients without a prior stroke [45]. The 
statement that candidates for the PEGASUS-TIMI 
54 trial strategy might mostly benefit from uninter-
rupted DAPT after the recommended 12-month 
course of DAPT after MI [45] is indeed supported 
by the analysis of the trial results [21], showing 
the highest benefit of DATT with ticagrelor in 
patients continuing on or re-starting after only 
a brief interruption of P2Y12 inhibition. On the 
other hand, according to the subgroup analysis of 
the COMPASS trial, the clinical benefit in terms 
of primary outcome, despite a clear trend, was not 
significant in patients enrolled within 2 years of 
MI. Unquestionable superiority of treatment with 
low rivaroxaban dose in combination with ASA 
over ASA alone was seen in subjects over 5 years 
after MI [35].
The superiority of DATT with low-dose rivar-
oxaban over ASA alone in patients with CAD and 
PAD was pointed out by Ramacciotti et al. [46]. The 
18% mortality reduction with rivaroxaban added to 
ASA is a unique finding; however, it is difficult to 
accept the statement that this strategy simply rep-
resents a paradigm shift for all patients requiring 
secondary prevention, because the COMPASS trial 
population is very different from the PEGASUS- 
-TIMI 54 trial population (Table 7). 
According to González-Juanatey et al. [47], 
during the first year after ACS, DAPT should be 
recommended, but after 12 months the ischemic 
and bleeding risk should be re-evaluated and among 
patients with high-risk features, and switching 
from DAPT to the COMPASS regimen should be 
strongly considered. This interesting concept, 
however, before being taken under consideration, 
should first be assessed in a clinical trial, because 
cessation of DAPT is associated with an increased 
risk of thrombotic events [14, 20], and evidence 
regarding the efficacy and safety of switching from 
a P2Y12 receptor inhibitor to rivaroxaban is lacking.
Besides antithrombotic therapy in a setting of 
low bleeding risk, multifactorial interventions in-
cluding lipid-lowering treatment in high-risk CAD 
patients might be a promising option to significantly 
improve the prognosis [48].
In order to apply a proper strategy of treatment 
to a post-ACS patient remaining in sinus rhythm, 
several factors need to be considered (Fig. 2): 
 — risk of cardiovascular ischemic events;
 — risk of bleeding events;
 — current antiplatelet treatment;
 — time since last ACS;
 — time since DAPT termination;
 — type of implanted stent;
 — known hypersensitivity to treatment with 
rivaroxaban and ticagrelor, prasugrel, or clopi-
dogrel;
 — comorbidities: history of ischemic stroke, re-
cent coronary artery bypass grafting, risk of 
bradycardia, renal insufficiency with estimated 
glomerular filtration rate < 15 mL/min, heart 
failure with ejection fraction < 30% or NYHA 
class III or IV, PAD or other atherothrombotic 
multiple vascular bed involvement (AMVBI).
For patients who discontinued their DAPT 
before 12 months after ACS due to intolerance of 
P2Y12 receptor inhibitor or ASA, treatment with 
one antiplatelet agent or a switch to another an-
tithrombotic agent should be considered.
Regardless of the treatment strategy chosen, 
the basis of effectiveness is patient adherence to 
medication. Therefore, health education aimed at 
explaining the purpose of therapy should be ap-
plied [49–54].
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Thus, implementation of a multidisciplinary 
approach involving a proper selection of patients 
with high risk for thrombosis and low risk for bleed-
ing may help to achieve long-term anti-ischemic 
benefits with low bleeding risk. The latter approach 
should be based on the assessment of individual 
patient’s propensity for thrombosis and bleeding 
in conjunction with demographic and clinical vari-
ables. Finally, stratification of patients for continued 
DAPT with ASA and low dose of ticagrelor vs. 
switching to combination therapy with ASA plus 
very low dose of rivaroxaban and finding the correct 
timing for this transition still poses a challenge. 
There is urgent need for a study investigating this 
issue. Potential utility of biomarkers or assays for 
platelet function and thrombin pathway function 
assessment remains an unexplored area in the 
stratification of patients for long-term therapy [55]. 
Summary
The comparison of the PEGASUS-TIMI 54 
and COMPASS trial patient characteristics clearly 
shows that each of these treatment strategies 
should be addressed at different groups of patients. 
A greater benefit in post-ACS patients with a high 
risk of ischemic events and without high bleeding 
risk may be expected with ASA and ticagrelor 60 mg 
b.i.d. when the therapy is continued without in-
terruption or with short interruption only after 
ACS. On the other hand, ASA and rivaroxaban 
2.5 mg b.i.d. seems to be a better option when 
indications for DATT appear after a longer time 
from ACS (more than 2 years) and/or from cessa-
tion of DAPT (more than 1 year) and in patients 
with multiple vascular bed atherosclerosis. Thus, 
both options of DATTs complement each other 
rather than compete, as can be presumed from the 
recommendations. However, a direct comparison 
between these strategies should be probably tested 
in future clinical trials. 
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DATT with rivaroxaban 2.5 mg b.i.d. DAPT with tricagrelor 60 mg b.i.d.
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or/and ACS < 2 years
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